Fusion Pharmaceuticals Inc. (FUSN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John Valliant
Employees:
90
270 LONGWOOD ROAD SOUTH, HAMILTON, CANADA L8P 0A6
289-799-0891

Fusion Pharmaceuticals Inc. focuses on developing radiopharmaceuticals as precision medicines. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Data derived from most recent annual or quarterly report
Market Cap 336.836 Million Shares Outstanding63.196 Million Avg 30-day Volume 52.825 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.99
Price to Revenue224.2649 Debt to Equity0.1711 EBITDA-95.555 Million
Price to Book Value1.0095 Operating Margin-10217.2566 Enterprise Value15.494 Million
Current Ratio12.734 EPS Growth-0.026 Quick Ratio12.117
1 Yr BETA 0.445 52-week High/Low 5.63 / 1.98 Profit Margin-10176.3274
Operating Cash Flow Growth-19.4324 Altman Z-Score-0.0116 Free Cash Flow to Firm -69.963 Million
Earnings Report2023-08-08

Are you looking for this stock instead?

View SEC Filings from FUSN instead.

View recent insider trading info

Fusion Pharmaceuticals Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FUSN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FUSN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-09 by VALLIANT JOHN
  • 4: filed on 2023-01-09 by RAWAT MOHIT
  • 4: filed on 2023-01-09 by LEAMON CHRISTOPHER P
  • 4: filed on 2023-01-09 by CROWLEY JOHN J
  • 4: filed on 2023-01-09 by BURAK ERIC
  • 4: filed on 2022-11-14 by KHUONG CHAU QUANG
  • 4: filed on 2022-11-07 by Bobilev Dmitri
  • 3: filed on 2022-11-07 by Bobilev Dmitri
  • 4: filed on 2022-08-11 by GANNON STEVEN
  • 4: filed on 2022-06-22 by PRESTON HEATHER

    • Events (8k)

  • 8-K: filed on 2023-05-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K/A: filed on 2023-02-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LEAMON CHRISTOPHER P CHIEF SCIENTIFIC OFFICER

    • Officer
    		 250,000 2023-01-05 1

    CROWLEY JOHN J CHIEF FINANCIAL OFFICER

    • Officer
    		 250,000 2023-01-05 1

    VALLIANT JOHN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 500,000 2023-01-05 1

    BURAK ERIC CHIEF TECHNOLOGY OFFICER

    • Officer
    		 250,000 2023-01-05 1

    RAWAT MOHIT PRESIDENT AND CBO

    • Officer
    		 300,000 2023-01-05 1

    KHUONG CHAU QUANG

    • Director
    		 42,093 2022-11-11 2

    BOBILEV DMITRI CHIEF MEDICAL OFFICER

    • Officer
    		 0 2022-11-07 2

    GANNON STEVEN

    • Director
    		 56,400 2022-08-11 2

    CAGNONI PABLO J

    • Director
    		 17,000 2022-06-14 1

    DUNCAN BARBARA GAYLE

    • Director
    		 17,000 2022-06-14 1

    PRESTON HEATHER

    • Director
    		 17,000 2022-06-14 1

    LEE PHILINA

    • Director
    		 17,000 2022-06-14 1

    O'LEARY JAMES J CHIEF MEDICAL OFFICER

    • Officer
    		 161,022 2022-02-01 0

    BERGSTROM DONALD A

    • Director
    		 17,000 2021-06-14 0

    ADAMS STREET PARTNERS LLC

    • 10% Owner
    		 No longer subject to file 2020-12-24 0

    JOHNSON & JOHNSON

    JOHNSON & JOHNSON INNOVATION - JJDC, INC.

    • 10% Owner
    		 No longer subject to file 2020-06-30 0

    TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

    BONDERMAN DAVID

    COULTER JAMES G

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2020-06-30 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED CAPITAL LLC

    • Director
    		 3,122,770 2020-06-30 0

    CHRISTENSON JOHAN

    • Director
    		 3,807,247 2020-06-30 0

    HEALTHCAP VII, L.P.

    HEALTHCAP VII GP S.A.

    • 10% Owner
    		 No longer subject to file 2020-06-30 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    • Director
    		 0 2020-06-25 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 22:15:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 21:45:05 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 21:15:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 20:45:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 20:15:06 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 19:45:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 19:15:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 18:45:04 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 18:15:03 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 17:45:05 UTC -14.1046 19.1746 400000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 17:15:04 UTC -14.1046 19.1746 550000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 16:45:03 UTC -14.1046 19.1746 550000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 16:15:04 UTC -14.1046 19.1746 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 15:45:04 UTC -14.1046 19.1746 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 15:15:04 UTC -14.1046 19.1746 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 14:45:04 UTC -14.1046 19.1746 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 14:15:03 UTC -14.1046 19.1746 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 13:45:03 UTC -12.846 17.916 100000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 13:15:04 UTC -12.846 17.916 250000
    FUSION PHARMACEUTICALS INC FUSN 2023-06-07 12:45:04 UTC -12.846 17.916 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments